Retatrutide
Also known as LY3437943
Retatrutide is an experimental weekly injection that hits three hormones at once (GLP-1, GIP, and glucagon), showing very large weight-loss results in trials. Not yet approved.
How one dose clears
modeled over ~6 half-lives- Half-life
- 6.0 days
- Reported range
- 5.0 days–7.0 days
- Time to peak (Tmax)
- 24 h
- Bioavailability
- 70%
- Steady state
- ~30 days
- Typical dose
- 1 mg
Investigational triple agonist (GLP-1 / GIP / glucagon receptor). Once-weekly. Not FDA-approved — in clinical trials.
Mechanism of action
Adds glucagon receptor agonism (raising energy expenditure) to GLP-1/GIP incretin effects, producing large weight-loss in phase 2 trials.
Investigational only. PK values are from early-phase publications and may change. Not available as an approved medicine.
References
Track Retatrutide for free
Log your doses and PeptideBuddy models Retatrutide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking freeFree. No card required.